Company profile: Elegen
1.1 - Company Overview
Company description
- Provider of cell-free DNA synthesis solutions, including ENFINIA DNA producing long, complex linear DNA up to 7kb with 99.999% per-base accuracy, shipped in 6 to 8 business days; high-complexity DNA synthesis for challenging sequences like long repeats and GC-rich regions, with delivery as fast as 10 business days; and an Early Access Program for pre-commercial products, including sequences longer than 15,000 base pairs.
Products and services
- Early Access Program: Offers select innovators pre-commercial DNA synthesis products, including sequences longer than 15,000 base pairs and high-complexity sequences
- ENFINIA DNA: A cell-free DNA synthesis technology producing long, complex, linear DNA up to 7kb in length with a 99.999% per base accuracy, shipped in 6 to 8 business days
- High Complexity DNA Synthesis: A high-complexity, rapid-access service for challenging DNA sequences—including long repeats and GC-rich regions—with delivery as fast as 10 business days
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Elegen
CC Bio
HQ: United Kingdom
Website
- Description: Provider of microbiome-focused therapeutic discovery for diagnosis and treatment. Products include Zeus, a platform to evaluate and optimize therapeutics for precise augmentation of microbial ecology; Athena, a platform developing genetic components for biosensor circuits that sense microbiome diseases; and Dionysus, a program engineering bacterial chassis to sense metabolic changes and record information across human tissues.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CC Bio company profile →
Biomatrica
HQ: United States
Website
- Description: Provider of biostability technologies to stabilize, process, store and ship biological samples at room temperature, preserving complex biological samples and assays based on the principles of anhydrobiosis; products include LBgard Blood Tubes for room‑temperature stabilization of blood samples.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biomatrica company profile →
BCF Life Sciences
HQ: France
Website
- Description: Provider of natural amino acids and derivatives for the pharmaceutical and health care industries. Specialises in extracting L-Cystine and L-Tyrosine of 100% traced origin and derivatives such as Carbocisteine. Offers L-Cystine, L-Tyrosine, Carbocisteine (expectorant API), Cysti-White, Kera-Diet keratin hydrolysate, and Leafamine (17 free amino acids) for food supplements, baby foods, and sustainable agriculture.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BCF Life Sciences company profile →
CytoSorbents
HQ: United States
Website
- Description: Provider of blood purification therapies and devices for treating life-threatening conditions, including CytoSorb to reduce excessive cytokines during ICU care and cardiac surgery; investigational DrugSorb-ATR to remove antithrombotic agents during cardiothoracic surgery; VetResQ for critically ill animals; ECOS-300CY for ex vivo organ perfusion; development-stage HemoDefend-RBC and HemoDefend-BGA for safer transfusions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CytoSorbents company profile →
ADC Bio
HQ: United Kingdom
Website
- Description: Provider of process technology for antibody drug conjugates (ADCs), helping drug developers address conjugation challenges in testing and production of ADC-based anti-cancer drugs, enabling faster, simpler and lower-cost development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ADC Bio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Elegen
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Elegen
2.2 - Growth funds investing in similar companies to Elegen
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Elegen
4.2 - Public trading comparable groups for Elegen
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →